Compare Enveric Biosciences Inc (ENVB) vs Sea Limited (SE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Sea Limited — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.80M), while Sea Limited trades at $95.47 (market cap $56.89B). The key difference: Sea Limited is far larger — about 8366.2× Enveric Biosciences Inc's market cap, and Sea Limited is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Sea Limited for 102 Days on average.
| ENVB | SE | |
|---|---|---|
Market Cap | $6.80M | $56.89B |
Volume | 64,867 | 5,359,457 |
Sector | Health | Consumer Cyclical |
52-Week High | $10.80 | $188.00 |
52-Week Low | $1.27 | $78.16 |
Typical Hold Time | 14 Days | 102 Days |
Enterprise Value | -$1.49M | $51.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495 with a 1.7% daily gain, showing technical bearish signals despite recent earnings beats. The company reported no revenue in 2025 with significant losses (-$8.77M net income), though valuation metrics appear low (EV/EBITDA 0.17, P/B 0.84). Recent news highlights patent approvals and positive preclinical data for non-hallucinogenic therapeutics.
The outlook remains speculative given the lack of revenue and substantial losses, offset by strong analyst support (75% buy rating) and promising drug development progress. Key risks include funding needs and clinical trial outcomes, while institutional sentiment appears cautiously optimistic about long-term pipeline potential.
Sea Limited (SE) trades at $94.66, down 1.94% with bearish technical signals despite strong fundamentals. The company shows robust revenue growth from $16.8B in 2024 to $22.9B in 2025, with net income reaching $1.58B. Recent earnings show mixed results with Q1 and Q2 2026 beats but a Q4 2025 miss. Analyst consensus remains strongly bullish with a $153.67 price target, representing 62% upside potential from current levels.
The stock presents a compelling growth opportunity with improving profitability and strong cash flow generation, though technical weakness and insider selling create near-term headwinds. Key risks include execution challenges in e-commerce profitability and competitive pressures in Southeast Asian markets. The disconnect between strong fundamentals and bearish technicals suggests potential for recovery if earnings momentum continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Sea Limited
Sea Limited offers information technology services. The Company provides online personal computer and mobile digital content, e-commerce, and payment platforms. Sea serves customers worldwide.
Read more on SE →
